Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

被引：20
|
作者：
Kelley, Michael J. [1 ,2 ,3 ]
Jha, Gautam [4 ]
Shoemaker, Debra [2 ]
Herndon, James E., II [2 ]
Gu, Lin [2 ]
Barry, William T. [2 ,5 ]
Crawford, Jeffrey [1 ,2 ]
Ready, Neal [1 ,2 ]
机构：
[1] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC USA
[3] Durham Vet Affairs Med Ctr, Med Serv, Durham, NC USA
[4] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA
[5] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
来源：
CANCER INVESTIGATION | 2017年 / 35卷 / 01期
关键词：
Non-small cell lung cancer; Src; gene expression; ERLOTINIB; TRIAL;
D O I：
10.1080/07357907.2016.1253710
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The Src pathway in activated in about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity of dasatinib in 37 patients with advanced, previously treated NSCLC. Among the 29 patients who underwent pre-treatment biopsy for RNA biomarker analysis, 25 were treated with dasatinib 70 mg twice daily. There were no responses. Five patients discontinued treatment due to toxicity. Three patients hadminor biopsy-related pneumothoraces. Given the lack of responses, no biomarkers were analyzed. Dasatinib 70 mg twice daily does not have activity nor is it well tolerated in unselected patients with advanced stage, previously treated NSCLC.
引用
收藏
页码：32 / 35
页数：4
相关论文
共 50 条
  • [31] Feasibility study of nivolumab and docetaxel in previously treated patients with advanced non-small cell lung cancer
    Miyazaki, Kazuhito
    Iwasawa, Shunichiro
    Nakamura, Yukiko
    Shimokawa, Tsuneo
    Yamanaka, Takeharu
    Takiguchi, Yuichi
    Okamoto, Hiroaki
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] A phase II study of vinorelbine in patients with advanced non-small cell lung cancer
    Evans, TRJ
    Mansi, JL
    Morgan, DAL
    Gyi, KM
    Banham, SW
    Milroy, R
    ONCOLOGY REPORTS, 1997, 4 (06) : 1337 - 1341
  • [33] A phase IINCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer
    Molina, Julian R.
    Nikcevich, Daniel
    Hillman, Shauna
    Geyer, Susan
    Drevyanko, Timothy
    Jett, James
    Verdirame, Joseph
    Tazelaar, Henry
    Rowland, Kendrith
    Wos, Edward
    Kutteh, Leila
    Nair, Suresh
    Fitch, Tom
    Flynn, Patrick
    Stella, Philip
    Adjei, Alex A.
    CANCER INVESTIGATION, 2006, 24 (04) : 382 - 389
  • [34] Efficacy of gefitinib in previously treated patients with advanced non-small-cell lung cancer: Phase II, multicenter study
    Park, Hee Sun
    Lee, Ki
    Jeon, Young June
    Kim, Young Chul
    Jang, Tae Won
    Jung, Maan Hong
    Son, Choon Hee
    Lee, Kwan Ho
    Kim, Ju Ock
    Kim, Sun Young
    ANNALS OF ONCOLOGY, 2006, 17 : 234 - 234
  • [35] Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer
    Besse, B.
    Leighl, N.
    Bennouna, J.
    Papadimitrakopoulou, V. A.
    Blais, N.
    Traynor, A. M.
    Soria, J. -C.
    Gogov, S.
    Miller, N.
    Jehl, V.
    Johnson, B. E.
    ANNALS OF ONCOLOGY, 2014, 25 (02) : 409 - 415
  • [36] A phase II trial of denileukin difititox- in previously treated, advanced non-small cell lung cancer (NSCLC).
    Lewis, MAG
    Shukla, R
    Kleykamp, B
    Jazieh, AR
    Hainsworth, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 689S - 689S
  • [37] Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy
    Yoh, Kiyotaka
    Kubota, Kaoru
    Kakinuma, Ryutaro
    Ohmatsu, Hironobu
    Goto, Koichi
    Niho, Seiji
    Saijo, Nagahiro
    Nishiwaki, Yutaka
    LUNG CANCER, 2007, 58 (01) : 73 - 79
  • [38] A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer
    Lee, Jae Jin
    Han, Ji-Youn
    Lee, Dae Ho
    Kim, Hyae Young
    Chun, Jong Ho
    Lee, Hong Gi
    Yoon, Seong Min
    Lee, Sung Young
    Lee, Jin Soo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 36 (12) : 761 - 767
  • [39] Randomized phase II study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer (NSCLC)
    Lynch, T. J.
    Fenton, D. W.
    Hirsh, V.
    Bodkin, D. J.
    Middleman, E.
    Chiappori, A.
    Halmos, B.
    Liu, H.
    Eton, O.
    Shepherd, W. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients
    Madan, Ankit
    Jones, Benjamin S.
    Bordoni, Rodolfo
    Saleh, Mansoor N.
    Jerome, Mary S.
    Miley, Deborah K.
    Jackson, Bradford E.
    Robert, Francisco
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 509 - 515
12345